Cardinal Health's CAH pharmaceutical segment has consistently demonstrated resilience and growth, driven by strong demand across brand, specialty, and generic pharmaceuticals. Historical ...

Cardinal Health (CAH) has surged to a new 52-week high of $136.44 per share, reflecting a robust ascent that defies the notion of “too late to buy.” With a market cap of $33 billion ...

Cardinal Health Inc. CAH is well-poised for growth, given its long-term supply agreements, diversified product portfolio and strong quarterly earnings. However, the possibility of losing a major ...